GENEVA, April 30 /PRNewswire/ -- Addex Pharmaceuticals will present at the BIO Business Forum during the Chicago BIO Convention, on May 5th, 2010 at 11:00am in Room 1.

Addexutilizes its unique proprietary platform technologies to discover and develop allosteric modulators for human health. Allosteric modulators are a different kind of orally available small molecule therapeutic agent, which we believe will offer a competitive advantage over classical drugs. The Addex pipeline demonstrates the productivity and broad potential of this unparalleled platform. The most advanced product, ADX48621 mGluR5 negative allosteric modulator (NAM), has completed early clinical testing and is scheduled to start mid-stage clinical testing in the fourth quarter of 2010 for Parkinson's disease levodopa-induced dyskinesia (PD-LID).

Our platform technologies already have proven their value through our relationships with four of the top 10 pharmaceutical companies in the world. Specifically, under an agreement with Ortho-McNeil-Janssen Inc., a Johnson & Johnson company, ADX71149, an mGluR2 positive allosteric modulator (PAM), is undergoing Phase I clinical testing and has potential for treatment of schizophrenia and anxiety. Under two separate agreements with Merck & Co., Inc., we are developing PAMs of mGluR4 and mGluR5 as drugs to treat Parkinson's disease and schizophrenia, respectively. In addition, SR-One, the corporate venture arm of GlaxoSmithKline, and Roche Venture Fund have made significant investments in Addex.

SOURCE Addex Pharmaceuticals